Advances in FL

CE / CME

Current and Emerging Therapeutic Advances in Follicular Lymphoma: A Class in Session

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: March 06, 2023

Expiration: March 05, 2024

John M. Burke
John M. Burke, MD
Jean Louise Koff
Jean Louise Koff, MD, MSc

Activity

Progress
1
Course Completed
Introduction

In this module, John M. Burke, MD, and Jean L. Koff, MD, MSc, discuss findings from key clinical trials investigating new and emerging immunotherapeutic approaches for treating patients with relapsed/refractory (R/R) follicular lymphoma (FL) and incorporating these therapies into practice.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with FL do you provide care for in a typical month?

Which of the following results has been reported with the use of approved CAR T-cell therapy (axicabtagene ciloleucel or tisagenlecleucel) in patients with R/R FL?

In addition to premedication with corticosteroids, antihistamine, and an antipyretic, which of the following is the recommended strategy to reduce CRS risk when treating a patient with R/R FL with the bispecific antibody mosunetuzumab-axgb?

A 77-year-old man was diagnosed with noncontiguous stage III FL. He received obinutuzumab plus cyclophosphamide/doxorubicin/vincristine/prednisone (O-CHOP) chemotherapy and had progressive disease after 15 months. Second-line therapy was initiated with lenalidomide and rituximab (R2). Eight months after completing the therapy, he developed symptoms, and biopsy confirmed relapsed FL. He has a past medical history of type 2 diabetes (A1C 7.3%) but is otherwise healthy and spends a lot of time with his adult son and grandchildren. During his consultation, he states, “I am concerned about these multiple recurrences and want a therapy I can start right away that isn’t associated with other malignancies.” Which of the following therapies would you recommend for this patient?